- Home
- News
News & Features
Brains Bioceutical Corp. is pleased to announce the completion of its US$30m Capital Raise
Watch on demand: DSM and Brains Bioceutical present at CT-Cann 2023 Leading Industry Session
March 9, 2023
Gain valuable insights into the early-stage drug development of cannabidiol (CBD) from industry experts Terry O’Regan, President of Brains Bioceutical, and Alexandru Zabara, Innovation Manager
Brains Bio Receives NSF’s First CBD Certification for EU GMP CBD API
January 16, 2023
The independent, third-party certification confirms that the company’s facility and EU GMP CBD products have attained NSF Certified for Sport® certification VANCOUVER, British Columbia, Nov.
Brains Bioceutical Opens UK’s Largest EU GMP-Grade Licensed Cannabinoid Research and Commercial Production Facility
October 5, 2022
Through its wholly owned subsidiary BSPG Laboratories, Brains Bio’s new facility is set to become a global research center for cannabinoid research, testing, and commercialization
Brains Bioceutical Appoints Former Executive Director of Glaxosmithkline Bill Purves As CCO
April 19, 2022
This announcement comes following the company’s previous appointment of former Bio Gen Managing Director as President of Brains Bio VANCOUVER, BC and UNITED KINGDOM, April 19, 2022 /PRNewswire/ – Bill
Brains to provide EU-GMP CBD API for Brazils first medical approved cannabis product
